12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fanapt iloperidone regulatory update

Vanda said in its 3Q12 earnings that it expects an oral hearing in the EU this month regarding the review of an MAA for iloperidone to treat schizophrenia. Vanda disclosed in its 2Q12 earnings that it requested an...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >